Search clinical trials for: Budesonide/formoterol (SYMBICORT) pMDI

Total 266 results

AstraZeneca
Parexel

Completed

A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers

Study is Being Conducted in Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Titratable Dosing in Moderate to Severe Asthmatics

Asthma
AstraZeneca

Completed

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Asthma

United States, Brazil, Bulgaria, Czech Republic, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, South Africa, United Kingdom, Vietnam, Germany, Philippines, Romania, Ukraine, Argentina, Chile, Puerto Rico, ... and more
Chiesi Farmaceutici S.p.A.

Completed

Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)

Chronic Obstructive Pulmonary Disease

China
AstraZeneca

Completed

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

Asthma

United States, Puerto Rico
AstraZeneca

Recruiting

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (LOGOS)

Asthma

United States, China, Czechia, Germany, South Africa, United Kingdom, Mexico, Turkey, Colombia, Russian Federation, Brazil, Israel, Greece, Portugal, Austria, Costa Rica, Saudi Arabia, Slovakia, Sweden, Puerto Rico
AstraZeneca

Recruiting

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (KALOS)

Asthma

United States, Canada, Denmark, Hungary, New Zealand, Poland, Spain, Korea, Republic of, Philippines, Italy, Argentina, Bulgaria, India, Japan, Vietnam, Taiwan, Thailand, Peru, Chile, Puerto Rico, Belgium, Australia, Netherlands, Romania
AstraZeneca

Completed

A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg (CHASE 3)

Asthma

United States, Mexico, Slovakia, Panama
Western Sky Medical Research
AstraZeneca

Completed

Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus) (WSMR2)

Asthma

United States
AstraZeneca

Completed

A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

Asthma

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

COPD

Japan
AstraZeneca

Completed

A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy (CHASE 2)

Asthma

United States, South Africa, Hungary, Bulgaria, Czech Republic, Poland
AstraZeneca

Completed

Symbicort Rapihaler Therapeutic Equivalence Study (ESTHER)

Bronchial Asthma

Bulgaria, Czech Republic, Poland, Hungary
AstraZeneca

Recruiting

A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS) (VATHOS)

Asthma

United States, Canada, Italy, Japan, Vietnam, Spain, Germany, Malaysia
AstraZeneca

Completed

A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects

Asthma

United States
AstraZeneca

Completed

A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects

Asthma

United States
AstraZeneca

Completed

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

Chronic Obstructive Pulmonary Disease

United States, Peru, South Africa, Argentina, Mexico, Brazil, Chile, Colombia, Venezuela
Pearl Therapeutics, Inc.

Completed

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD (telos)

Chronic Obstructive Pulmonary Disorder

United States, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Czechia
Allergy and Asthma Center of El Paso
GlaxoSmithKline

Unknown

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

Asthma

United States
AstraZeneca

Completed

Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT

Asthma
AstraZeneca

Completed

Long-Term Safety of Symbicort in Asthmatic Children - SAPLING

Asthma
AstraZeneca

Completed

Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD

Chronic Obstructive Pulmonary Disease

China
AstraZeneca

Completed

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease (RISE)

COPD Patients

United States, Spain, Bulgaria, Mexico, Poland, South Africa, Germany, Argentina, Chile, Czechia, Puerto Rico
Istituto per la Ricerca e l'Innovazione Biomedica

Completed

The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma

Asthma

Italy
AstraZeneca

Completed

Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia (SMARTASIA)

Asthma

China, Taiwan, Thailand, India, Indonesia
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product (BUFODIL)

Asthma

Bulgaria
AstraZeneca

Completed

Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

Asthma

Croatia
AstraZeneca

Completed

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

Chronic Obstructive Pulmonary Disease

United States, Czech Republic, Poland, South Africa, Netherlands
Medical University of Warsaw

Completed

Optimal Type of Inhaler in Cough Variant- or Cough Predominant Asthma

Asthma | Cough Variant Asthma

Poland
Actavis Inc.
Teva Pharmaceuticals USA

Completed

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

Asthma

United States
AstraZeneca

Completed

Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma (Spacer)

Asthma

Russian Federation, Hungary, Poland
AstraZeneca

Completed

Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans (Titan)

Asthma

United States
AstraZeneca

Completed

Gemini Symbicort pMDI

Mild or Moderate Asthma
AO GENERIUM

Completed

An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma (NAP)

Bronchial Asthma

Russian Federation
AstraZeneca

Completed

Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients (SUMIRE)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Poland, Russian Federation, Vietnam, Philippines, Ukraine, Japan, Taiwan, India
AstraZeneca

Completed

Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler (REALITY)

Perception of Physicians & Patients of AMD
AstraZeneca

Completed

Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia (SMARTER)

Asthma

Malaysia
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte (ADECO)

Asthma

Germany
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

COPD

United States
AstraZeneca

Completed

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

Chronic Obstructive Pulmonary Disease (COPD)

Germany
Mundipharma Research Limited

Completed

Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

Asthma

Poland, Bulgaria, Romania, India, Hungary
Pearl Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (KRONOS)

COPD

United States, Canada, China, Japan
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler

Healthy

Finland
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma (ELIOT)

Asthma

United Kingdom
AstraZeneca

Completed

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients

Asthma | Airway Inflammation

United Kingdom
Research in Real-Life Ltd
Teva Branded Pharmaceutical Products R&D, Inc.; University of Sydney; The University... and other collaborators

Completed

Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices (HCP-ELIOT)

Asthma
University Hospital, Antwerp
AstraZeneca

Completed

Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.

Chronic Obstructive Pulmonary Disease

Belgium
AstraZeneca

Completed

A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan

Chronic Obstructive Pulmonary Disease

Japan
Orion Corporation, Orion Pharma

Completed

Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Asthma

Finland

3

Subscribe